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Background: Anthroposophic treatment includes special artistic and physical therapies and special medications. We here
report an update to a previously published study of anthroposophic treatment for chronic diseases, including more
patients and a longer follow up. The Anthroposophic Medicine Outcomes Study (AMOS) was a prospective observational
cohort study of anthroposophic treatment for chronic indications in routine outpatient settings in Germany.
Anthroposophic treatment was associated with improvements of symptoms and quality of life. Previous follow-up
-analyses have been performed after 24 months or, in subgroups of patients enrolled in the period 1999-2001, after
48 months. We conducted a 48-month follow-up analysis of all patients enrolled in AMOS in the period 1999-2005.
Methods: 1,510 outpatients aged 1-75 years, starting anthroposophic treatment for chronic conditions in routine German
outpatient settings, participated in a prospective cohort study. Main outcomes were Symptom Score (primary outcome,
mean symptom severity on numerical rating scales), SF-36 Physical and Mental Component scores in adults, and
disease-specific outcomes in the six most common diagnosis groups: asthma, anxiety disorders and migraine (numerical
rating scales), depression (Center for Epidemiological Studies Depression Scale), attention deficit hyperactivity symptoms
(FBB-HKS Total score), and low back pain (Hanover Functional Ability Questionnaire, Low Back Pain Rating Scale).
Results: Median disease duration at baseline was 3.5 years. From baseline to 48-month follow-up all ten outcomes
improved significantly (p < 0.001 for all pre-post comparisons). Standardised Response Mean effect sizes were large (range
0.84-1.24 standard deviations) for seven comparisons, medium for two comparisons (SF-36 Mental Component: 0.60, Low
Back Pain Rating Scale: 0.55), and small for one comparison (SF-36 Physical Component: 0.39). Symptom Score improved
significantly with large effect sizes in adults and children, and in the four main anthroposophic therapy modality groups
(art therapy, eurythmy therapy, rhythmical massage therapy, medical therapy).
Conclusions: This 48-month follow-up analysis confirmed previous analyses from the AMOS study. Outpatients receiving
anthroposophic treatment for chronic indications had sustained, clinically relevant improvements of symptoms and quality of life.Background
We here report an update to a previously published
study of anthroposophic treatment for chronic diseases
[1], including more patients and a longer follow up.
Chronic diseases are the most common cause of dis-
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reproduction in any medium, provided the or[2]. Many patients with chronic disease use complemen-
tary therapies [3], often provided by their physicians.
Anthroposophic medicine (AM), founded by Rudolf
Steiner and Ita Wegman in the 1920s [4], is a comple-
mentary therapy system. AM acknowledges a spiritual-
existential dimension in man, which is assumed to interact
with psychological and somatic levels in health and disease.
AM therapy for chronic disease aims to counteract consti-
tutional vulnerability, stimulate salutogenetic self-healing
capacities, and strengthen patient autonomy [5-7]. This is
sought to be achieved by counselling [6]; by non-verbalLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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or speech exercises [12]; by eurythmy movement exercises
[13,14]; by special physical therapies [15,16]; and by spe-
cial AM medications [17,18].
AM is provided by physicians (counselling, medications) in
collaboration with non-medical practitioners (e.g. eurythmy,
art therapy, physical therapy) in hospitals and outpatient
settings. AM treatment is used alone or in combination
with conventional treatment as needed. In Europe 24
hospitals (including 14 with accident & emergency services)
offer AM therapy, and an estimated 17.000 physicians in
outpatient settings prescribe AM medications [19].
Since AM therapy aims for sustained improvement [6,7],
long-term clinical outcomes are particularly important in
the evaluation of AM therapy. An opportunity to study
such long-term outcomes was given by the Anthroposophic
Medicine Outcomes Study (AMOS). AMOS was a pro-
spective observational cohort study of AM therapy for
chronic indications in routine outpatient settings in
Germany [1]. The study was initiated by a health insurance
company in conjunction with a health benefit program.
AM treatment was associated with improvements of symp-
toms and quality of life. Previous follow-up-analyses have
been performed after 24 months or, in subgroups of pa-
tients enrolled in the period 1999-2001, after 48 months
[1,20-30]. We here present a 48-month follow-up analysis
of all patients enrolled in AMOS in the period 1999-2005.Methods
Study design and research questions
This is the final follow-up analysis of a prospective
observational cohort study of AM therapy for chronic
diseases in routine outpatient settings (AMOS) [1]. Com-
pared to previous outcome analyses of the AMOS study,
the present analysis was an extension regarding:
 recruitment period: 1999-2005 vs. 1999-2001 in
previous analyses [1,20-24]
 last follow-up: 48 months vs. 24 months in previous
analyses [1,25-30]
The research questions concerned the following items:
A. Disease symptoms and quality of life at 48- month
follow-up (main research question)
B. Patient satisfaction after 6 and 12 months
C. Safety in months 0-24
D. Continuity of the physician-patient relationship at
48-month follow-up.
For items A-C, the research question was: Can findings
from previous analyses that were restricted to patient
subgroups (items A-C) or earlier follow-ups (item A) beconfirmed in the present full sample and at 48 months
follow-up, respectively?
For item D, previously not analysed, the research question
was: Which proportion of the patients are, after 48 months,
still being treated by the same physician who had enrolled
them into the study?
Setting, participants, and therapy
All physicians certified by the Physicians’ Association for
Anthroposophical Medicine in Germany and working in
an office-based practice or outpatient clinic in Germany
were invited to participate in the AMOS study. The par-
ticipating physicians were asked to recruit consecutive
outpatients starting AM therapy under routine clinical
conditions. Patients enrolled from 1 January 1999 to 31
December 2005 were included in the present analysis
if they fulfilled the eligibility criteria (patients enrolled
before 1 January 1999 had no follow-up documentation
beyond 12 months). Inclusion criteria were:
1. Outpatients aged 1-75 years.
2. Starting AM therapy for any indication (main diagnosis)2a: AM-related consultation of at least 30 minutes
followed by new prescription of AM medication, or
2b: referral to AM treatment by non-medical
therapist: art therapy, eurythmy therapy or
rhythmical massage therapy.
3. Duration of main diagnosis of at least 30 days at
study enrolment.
Patients were excluded if they had previously received
the AM therapy in question (see inclusion criteria no. 2)
for their main diagnosis. AM therapy was evaluated as a
whole system [31] with subgroup analyses of adults and
children and in previously published diagnosis groups
[24,26-30] and therapy modality groups [20-23]. In sub-
group analyses of patients according to AM therapy
modality, patients fulfilling inclusion criteria 2a as well
as 2b were analysed in group 2b.
Clinical outcomes
Clinical outcomes were documented after 0, 3, 6, 12, 18,
24, and 48 months. In this analysis clinical outcomes
were assessed at 48-month follow-up.
Primary outcome
 Primary outcome was Symptom Score, a compound
measure of the symptoms for which the patients had
sought medical attention. At baseline, the patients
(caregivers in children) documented one to six
symptoms, ranked in order of decreasing
importance, and assessed the intensity of each
symptom on a numerical rating scale [32] from 0
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follow-up, the patients documented the intensity of
the same symptoms which they had documented at
baseline. Symptom Score was the average severity of
all documented symptoms per patient at each
documentation point. This symptom rating was used
as primary outcome measure for the present analysis
because it was the only clinical outcome
documented in all patients at 48-month follow-up.
Secondary outcomes
 First ranked symptom at baseline (see above) on a
numerical rating scale 0-10 [32]
 Generic quality of life: SF-36 Physical and Mental
Component summary measures and the eight SF-36
scales (0-100) [33] for adults aged 17-75 years
(quality of life was not documented in children at
48-month follow-up)
 Depressive symptoms: Center for Epidemiological
Studies Depression Scale, German version (CES-D,
0-60) [34,35] for adults enrolled after 1 October
1999 (depressive symptoms were not documented
in children, and CES-D was not documented at
48-month follow-up in patients enrolled before 1
October 1999)
 Disease-specific outcomes for the most frequent
diagnosis groups: Anxiety Disorders, Asthma,
Attention Deficit Hyperactivity Symptoms,
Depression, Low Back Pain, and Migraine
Other outcomes
 Use of AM art, eurythmy and rhythmical massage
therapy in months 0-24 was documented by the
therapists in a therapy diary.
 Therapy outcome rating and satisfaction with
therapy were documented by the patients on
numerical rating scales (0-10) after 6 and
12 months.
 The continuity of the physician-patient relationship
was documented after 6, 12, 18, 24, and 48 months.
 Suspected adverse reactions to medications or
therapies were documented by the patients after 6,
12, 18, and 24 months, and by the physicians after
6 months (for patients enrolled before 1 April 2001
also after 3, 9, and 12 months). The documentation
included suspected cause, intensity (mild/moderate/
severe = no impairment/some impairment/complete
impairment of normal daily activities), and therapy
discontinuation because of adverse reactions.
 Serious adverse events (death, life-threatening
condition, acute in-patient hospitalization, new
disease or accident causing permanent disability,congenital anomaly, new malignancy) were
documented by the physicians throughout the study
months 0-24.
Data collection
All data were documented with questionnaires returned
in sealed envelopes to the study office. The physicians
documented eligibility criteria; all other items were doc-
umented by the patients or caregivers, unless otherwise
stated. The patient responses were not made available
to the physicians. The physicians were compensated
40 Euro (after March 2001: 60 Euro) per included
and fully documented patient, while the patients
received no compensation.
The data were entered twice by two different persons
into Microsoft® Access 97. The two datasets were com-
pared and discrepancies resolved by checking with the
original data.
Quality assurance, adherence to regulations
The study was approved by the Ethics Committee of the
Faculty of Medicine Charité, Humboldt University, Berlin,
Germany, and was conducted according to the Declar-
ation of Helsinki and largely following the ICH Guideline
for Good Clinical Practice E6. Written informed consent
was obtained from all patients before enrolment.
Data analysis
The data analysis was performed on all patients fulfilling
the eligibility criteria, using PASW® Statistics 18.0 (SPSS
Inc., Chicago, Ill, USA) and StatXact® 9.0.0 (Cytel Software
Corporation, Cambridge, MA, USA). Diagnoses were coded
according to the International Classification of Diseases,
Tenth Revision (ICD-10).
For bivariate analyses of continuous data with approxi-
mately normal distribution the two-tailed t-test was used;
for independent samples with skewed data the Mann–
Whitney U-test was used. For binominal data the two-
tailed McNemar test and Fisher’s exact test were used.
Significance criteria were p < 0.05. Since this was a de-
scriptive study, no adjustment for multiple comparisons
was performed [36].
Pre-post effect sizes were calculated as Standardised Re-
sponse Mean (= mean change score divided by the standard
deviation of the change score) and classified as minimal
(< 0.20), small (0.20-0.49), medium (0.50-0.79), and large
(≥ 0.80) [37,38]. Clinical relevance criteria for pre-post
changes were Standardised Response Mean ≥ 0.50 [39].
For analysis of clinical outcomes, missing values were
replaced with the last value carried forward. Accordingly,
each clinical outcome and subgroup analysis comprised
all patients in the respective group with available base-
line scores (in total 98.7%, n = 17,994 of 18,223 scores
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data were not replaced.
All suspected adverse reactions were classified as reported
adverse reactions and subject to descriptive analysis. The
frequency of reported reactions from AM medications in
this analysis (patients enrolled January 1999 to December
2005) were compared to the frequency of confirmed reac-
tions in a previously published detailed safety analysis
from AMOS (patients enrolled January 1999 to March
2001) [40]. Serious adverse events were assessed with
regard to a possible causal relationship to ongoing medi-
cation and non-medication therapy by the study physi-
cians and the first author.
Results
Participating physicians and therapists
A total of 151 physicians enrolled patients. These physi-
cians did not differ significantly from eligible physicians
without study patients (n = 167) regarding gender (propor-
tion of male physicians: 57.0% vs. 64.7%, p = 0.134) and
setting (proportion of primary care physicians: 85.4% vs.
82.1%, p = 0.876). Significant differences were found re-
garding the number of years in practice (mean ± standard
deviation 18.0 ± 7.4 years vs. 20.3 ± 9.5 years in physicians
with and without study patients, respectively, p = 0.011,
mean difference 2.3 years, 95% confidence interval [95%-CI]
0.5-4.0 years) and age (46.8 ± 7.0 years vs. 49.5 ± 8.5 years,
p = 0.003, mean difference 2.6 years, 95%-CI 0.9-4.4 years).
The patients who had been referred to AM art, eurythmy
or rhythmical massage therapy were treated by 275 dif-
ferent therapists. Comparing these therapists to eligible
therapists without study patients (n = 911), no significant
differences were found regarding age (mean 49.2 ± 8.1 years
vs. 50.6 ± 9.8 years, p = 0.068), gender (81.5% vs. 80.7%
women, p = 0.861) or the number of years since therapy
school graduation (12.1 ± 7.1 vs. 13.5 ± 9.2 years, p = 0.225).
Patient recruitment and follow-up
From 1 January 1999 to 31 December 2005, a total of
1,678 patients aged 1-75 years were assessed for eligibility.
Of these patients, 1,510 fulfilled all eligibility criteria and
were included in the present analysis. Of the 168 patients
who were not included, 32 did not fulfil the eligibility cri-
teria for the analysis (disease duration < 30 days: n = 32)
and 136 patients were potentially eligible but were not
included in the AMOS study for the following reasons:
patients’ baseline questionnaire missing (n = 57), patients’
and physicians’ baseline questionnaire dated > 30 days
apart (n = 49), previous or ongoing use of AM therapy
(n = 19), no informed consent (n = 8), other reasons (n = 3).
The included patients (n = 1,510) and the patients not
included but potentially eligible (n = 136) did not differ
significantly regarding age, gender, diagnosis, disease
duration or baseline Symptom Score.A total of 71.7% (n = 1,083/1,510) of patients were en-
rolled by general practitioners, 12.2% by paediatricians,
6.4% by internists, 6.1% by gynaecologists, and 3.6% by
other specialists. The physicians’ settings were primary
care practices (82.1% of evaluable patients, n = 1,212/
1,477), referral practices (11.2%), and outpatient clinics
(6.6%). Each physician enrolled 1-4 patients (51.0%, n =
77/151 physicians), 5-9 patients (21.9%, n = 33), 10-19
patients (15.2%, n = 23) or ≥ 20 patients (11.9%, n = 18),
with a median of 4.0 patients enrolled per physician
(range 1-55 patients, interquartile range [IQR] 2.0-11.0
patients, average 10.0 patients).
The last patient follow-up ensued on 16 May 2010. A
total of 96.0% (n = 1,450/1,510) of patients returned at
least one follow-up questionnaire. The patients were
administered a total of 9,060 follow-up questionnaires,
out of which 7,114 (78.5%) were returned. Follow-up
rates were 94.5% (n = 1,377/1,510), 91.2%, 86.7%, 82.9%,
76.6%, 73.2%, and 60.5% after 3, 6, 12, 18, 24, and
48 months, respectively. Respondents (= patients who
did return the follow-up questionnaire, n = 914) and
non-respondents (n = 596) of the 48-month follow-up
did not differ significantly regarding age, gender, diag-
nosis or disease duration. Baseline Symptom Score was
6.0 ±1.8 points in respondents and 6.3 ±1.7 points in
non-respondents (p < 0.001, mean difference 0.3 points,
95%-CI 0.2-0.5 points). For non-respondents of the
48-month follow-up, the last available questionnaire was
returned after average 15.7 months. In respondents of
the 48-month follow-up Symptom Score was (interpo-
lated average) 3.40 points after 15.7 months and 2.48
points after 48 months.
Baseline characteristics
The patients were recruited from 15 of 16 German federal
states. Age groups were 1-19 years: 29.8% (n = 450/1,150),
20-39 years: 25.4%, 40-59 years: 35.2%, and 60-75 years:
9.6% with a median age of 37.0 years (IQR 12.3-47.1 years,
mean 33.8 ± 19.4 years). A total of 69.8% (n = 1,054/1,510)
of all patients and 81.5% (n = 975/1,074) of adults aged
17-75 were women.
Compared with the German population, adult patients
had higher educational and occupational levels and were
less frequently regular smokers, daily alcohol consumers,
overweight, and unemployed, whereas more patients en-
gaged in sports than in the population. Socio-demographic
status was similar to the population regarding income,
severe disability status, and the proportion living alone,
and less favourable for work disability pension and sick-
leave (Table 1). Socio-demographic characteristics of the
children have been presented elsewhere [25].
Most frequent main diagnoses, classified by the ICD-10
diagnosis chapters were F00-F99 Mental and behavioural
disorders (35.2%, n = 532/1,510), M00-M99 Diseases of
Table 1 Socio-demographic characteristics of adult patients (age 17-75 years, n = 1074)
Item Subgroup Patients German population
N % % Reference
Education [41] [42]
-Low (grade 1) 184 17.1% 43% [43]
-Intermediate (grade 2) 530 49.3% 43%
-High (grade 3) 360 33.5% 14%
Wage earners 39/1074 3.6% 18% [42]
Unemployed during last 12 months Economically active patients 37/618 6.0% 10% [42]
Living alone 208/1069 19.5% 21% [42]
Net family income < 900 € per month 160/871 18.4% 16% [42]
Alcohol use daily (patients) vs almost daily (Germany) Male 12/198 6.1% 28% [44]
Female 19/875 2.2% 11%
Regular smoking Male 26/199 13.1% 37% [45]
Female 92/873 10.5% 28%
Sports activity≥ 1 hour weekly Age 25-69 484/887 54.6% 39% [46]
Body mass index < 18.5 (low) Male 7/196 3.6% 1% [42]
Female 61/863 7.1% 4%
Body mass index ≥ 25 (overweight) Male 64/196 32.7% 56% [42]
Female 219/863 25.4% 39%
Permanent work disability pension 204/1072 19.0% 3% [47]
Severe disability status 116/1072 10.8% 12% [48]
Sick leave days in the last 12 months: mean (standard deviation) Economically active patients 32.6 (67.3) 17.0 [49]
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J00-J99 Diseases of the respiratory system (9.9%), and
G00-G99 Diseases of the nervous system (7.2%). The most
frequent diagnosis groups are listed in Table 2. Disease
duration at baseline was 1-2 months in 4.4% (n = 67/1510)
of patients, 3-5 months in 5.0%, 6-11 months in 8.5%,
1-4 years in 38.3%, and ≥ 5 years in 43.7%, with a median
duration of 3.5 years (IQR 1.0-8.5 years, mean ± standard
deviations 6.6 ± 8.2 years). A current comorbid disease
was present in 76.4% (n = 1,154/1,510) of patients, with a
median of 1.0 (IQR 1.0-2.0) comorbid diseases per patient.
The most common comorbid diagnoses were M00-M99
Diseases of the musculoskeletal system and connective
tissue (14.7%, n = 350/2,378 diagnoses), F00-F99 Mental
and behavioural disorders (13.6%), J00-J99 Diseases of
the respiratory system (9.4%), I00-I99 Diseases of the cir-
culatory system (8.3%), and E00-E99 Endocrine, nutri-
tional and metabolic diseases (8.1%).
Therapy
At enrolment 19.4% (n = 293/1,510) of patients ful-
filled inclusion criterion 2a (AM-related consultation
of ≥ 30 minutes followed by new prescription of AM
medication), 44.3% fulfilled inclusion criterion 2b (referral to
AM eurythmy/art/massage therapy), and 36.3% fulfilledinclusion criteria 2a and 2b. The duration of the
consultation with the AM physician at enrolment was <
30 min in 51.4% (n = 776/1,510) of patients, 30-44 min
in 23.6%, 45-59 min in 11.5%, and ≥ 60 min in 13.5%
of patients.
Of the 1,217 patients who were referred to AM art,
eurythmy or massage therapy, 86.8% (n = 1,065) had the
planned AM therapy within the first 24 months, 0.5%
did not have AM therapy, and for 12.6% the AM therapy
documentation is incomplete. AM therapies used were
eurythmy therapy (66.4%, n = 707 of 1,065 patients who
had the planned AM therapy), rhythmical massage therapy
(10.9%), and art therapy (22.7%, n = 242) with the therapy
modalities painting/drawing/clay (54.1%, n = 131 of the
242 patients who had art therapy), speech exercises (33.5%),
and music (12.4%). The AM therapy started median 13
(IQR 2-41) days after enrolment. Median therapy duration
was 119 days (IQR 84-190 days), median number of ther-
apy sessions was 12 (IQR 10-20). AM medications were
used by 61.2% (n = 924/1,510) of patients in months 0-6
and by 71.7% in months 0-24.
Continuity of physician-patient-relationship
At 48-month follow-up 62.8% of the evaluable patients
(n = 575/915) were still being treated by the AM physician
Table 2 Most frequent diagnosis groups






Depression 135 17-70 1999-2005* Depressed mood plus ≥2 of 6 defined core
symptoms of depression; symptom
duration≥ 6 months; CES-D≥ 24 points
CES-D (0-60) [24]
Asthma 90 2-70 1999-2005 Physician’s diagnosis (ICD-10 J45) Average Asthma Severity (NRS, 0-10) [28]
Low Back Pain 75 17-75 1999-2005 Low back pain of ≥ 6 week duration.
Exclusion: previous back surgery,
11 specific diagnoses
HFAQ (0-100), LBPRS (0-100), [26]
Anxiety Disorders 64 17-75 1999-2005 Physician’s diagnosis (ICD-10 F40-F42 or F43.1) Anxiety Severity (NRS, 0-10) [27]
ADHD Symptoms 61 3-16 2001-2005 Physician’s diagnosis (ICD-10 F90),
symptom duration ≥ 6 months
FBB-HKS Total score (0-3) [29]
Migraine 45 17-75 1999-2005 Criteria of the International Headache
Society [50]
Average Migraine Severity (NRS, 0-10) [30]
CES-D Center for Epidemiological Studies Depression Scale, German version, ICD-10 International Classification of Diseases, Tenth Revision. *Recruitment period for
previously published 4-year analysis [24]: 1998-2001. NRS Numerical rating scales [32], HFAQ, Hanover Functional Ability Questionnaire [51], LBPRS Low Back Pain
Rating Scale Pain Score [52], ADHD Attention Deficit Hyperactivity Disorder, FBB-HKS Fremdbeurteilungsbogen für Hyperkinetische Störungen (parents’ questionnaire for
ADHD core symptoms) [53,54].
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longer being treated by the AM physician were “positive”:
full recovery or improvement (13.1% of all evaluable
patients, n =120/915), “negative”: choice of other treat-
ment or dissatisfaction with the physician (12.0%, n = 110),
and “neutral”: practical reasons, e. g. patient or physician
had moved, physician had stopped practicing or financial
reasons (9.3%, n = 85), and other reasons (2.7%, n = 25).
The 0-48 month Symptom Score improvement did not
differ significantly between patients with or without on-
going treatment by the AM physician (p = 0.234), while
in the latter group, patients with “positive” reasons for
not being treated had more improvement than patients
with “negative” reasons (mean difference 1.96 points,
95%-CI 1.29-2.62 points, p < 0.001) (Table 3).
Clinical outcomes at 48-month follow-up
At 48-month follow-up all clinical outcomes in all analysed
groups were significantly improved from baseline (p < 0.001
for all 26 comparisons, Table 4, Figures 1, 2 and 3). For
the primary outcome Symptom Score, an improvement
of at least 50% of baseline scores was observed in 50.2%
(n = 754/1,501) of patients. For symptom assessments
(16 comparisons), Standardised Response Mean effect
sizes were large for 14 comparisons and medium for two
comparisons (CES-D in all adults, Low Back Pain Rating
Scale Pain Score in Low Back Pain group). For generic
quality of life assessments (SF-36 scores, 10 comparisons),
effect sizes were medium for five comparisons and small
for five comparisons.
The 0-48 month differences in the present analysis
(Table 4) were compared to corresponding long-term
pre-post differences of each outcome and subgroup intwelve previously published analyses from the AMOS
study [1,20-30]. The compared analyses differed in the
following aspects:
 Six previous analyses [1,20-24] comprised patients
enrolled 1999-2001, while the present analysis
comprised patients enrolled 1999-2005.
 Seven previous analyses [1,25-30] referred to 0-24
month differences, while the present analysis
referred to 0-48 month differences.
 In ten previous analyses [1,20-28] the pre-post
differences had been calculated as average baseline
scores minus average scores at the last follow-up
in patients with available scores at baseline and
follow-up, respectively, while the present analysis
was performed on patients with available scores at
baseline after replacement of missing values with
the last value carried forward.
Each of the twelve previously published analyses [1,20-30]
comprised pre-post differences of one or several clinical
outcomes, yielding a total of 24 pre-post differences. These
were compared to the 24 corresponding pre-post differ-
ences in the present analysis (of 26 pre-post differences in
the present analysis [Table 4], two pre-post differences
had not been previously published: first ranked symptom,
CES-D in all adults). For 21 comparisons the differences
between the two analyses were minimal (less than 0.2
standard deviations [SD]) while three comparisons showed
small differences indicating less improvement in the present
analysis: Symptom Score in rhythmical massage therapy
group (0.21 SD difference), Average Asthma Severity
(0.29 SD), and Average Anxiety Severity (0.40 SD).
Table 3 Symptom score 0-48 months
Symptom score
(0-10)
N 0 months 48 months 0-48 month difference
Mean (95%-CI) Mean (95%-CI) Mean (95% CI) P-value
All evaluable patients 908 5.96 (5.84-6.07) 2.75 (2.62-2.88) 3.21 (3.05-3.37) <0.001
Still being treated by study physician?
-Yes 571 5.85 (5.70-6.01) 2.72 (2.57-2.88) 3.13 (2.94-3.33) <0.001
-No 337 6.13 (5.94-6.31) 2.79 (2.55-3.03) 3.34 (3.06-3.61) <0.001
–No: “Positive” reasons 120 6.09 (5.77-6.41) 1.52 (1.28-1.76) 4.57 (4.17-4.96) <0.001
–No: “Neutral” reasons 108 6.13 (5.81-6.46) 3.43 (3.00-3.85) 2.71 (2.29-3.12) <0.001
–No: “Negative” reasons 109 6.16 (5.83-6.49) 3.55 (3.09-4.00) 2.61 (2.07-3.15) <0.001
Respondents at 48-month follow-up with available baseline score. CI Confidence interval. “Positive” reasons: full recovery or improvement. “Neutral” reasons:
practical reasons (e. g. patient or physician had moved, physician had stopped practicing or financial reasons) or other reasons. “Negative” reasons: choice of
other treatment or dissatisfaction with physician.
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Patient therapy outcome rating and satisfaction after 6
and 12 months
At 6-month follow-up the patients’ ratings of therapy out-
come (0 = no help at all, 10 = helped very well, n = 1,275)
were mean ± standard deviation 7.23 ± 2.39 points; patient
satisfaction with therapy (0 = very dissatisfied, 10 = very
satisfied, n = 1,273) was 7.94 ± 2.20 points. Between 6- and
12-month follow-ups therapy outcome ratings did not
change significantly, while therapy satisfaction decreased
by average 0.31 points (95%-CI 0.18-0.45 points, p < 0.001,
n = 1,083).
Safety in months 0-24
Adverse reactions from AM therapies and medications
were infrequent and mostly of mild-to-moderate intensity
(Table 5). Adverse drug reactions were reported signifi-
cantly less frequently from AM medications (4.4% of users,
n = 48/1,083) than from non-AM medications (14.8% of
users, n = 173/1,167) (p < 0.001, odds ratio for reported
reaction from AM vs. non-AM reaction: 0.27, 95%-CI
0.19-0.37).
Serious adverse events occurred in 2.3% (n = 34/1,510)
of patients. The events were acute hospital admissions
(n = 16), deaths (n = 15), new malignancy (n = 1), life-
threatening ileus (n = 1), and permanent disability from
whiplash injury (n = 1). Death causes in the 15 patients
who died were malignant neoplasms (n = 12), AIDS (n = 1),
pneumonia (n = 1), and accident or suicide in a patient
hospitalised for severe depression (n = 1). None of the ser-




This is a four-year follow-up analysis of the largest clinical
outcome study of AM treatment for chronic disease so far.
We studied 1,510 outpatients starting comprehensive AM
treatment (physician counselling, art therapy, eurythmytherapy, rhythmical massage therapy and/or AM medica-
tions) for mental, musculoskeletal, respiratory or neuro-
logical disorders or other chronic conditions. At four-year
follow-up, 76% of the evaluable patients were either still
being treated by the AM physician who had enrolled them
into the study (63% of the patients) or were no longer re-
ceiving treatment because they had improved or recovered
(13%). Previous analyses of different age, diagnosis and
therapy modality groups had shown clinically relevant
improvements of symptoms and quality-of-life following
AM treatment [1,20-30]. The present follow-up-analysis
confirmed these improvements in a larger sample and
showed that the improvements were maintained at four-
year follow-up. Adverse reactions to AM medications or
therapies were infrequent and mostly of mild-to-moderate
intensity.
Strengths and limitations
Strengths of the AMOS study and this analysis include a
large sample size, a long follow-up period, the combin-
ation of generic and disease-specific outcome measures,
the assessment of a broad range of AM therapy modal-
ities, and a high representativeness due to the participa-
tion of 47% of eligible AM physicians and 23% of eligible
AM therapists in Germany. The participating physicians
and therapists resembled eligible but not participating
AM physicians and AM therapists with respect to demo-
graphic characteristics, and the included patients resembled
not included patients regarding baseline characteristics.
These features suggest that the study to a high degree mir-
rors contemporary AM use in German outpatient settings.
The main research question of the present analysis
concerned the magnitude of long-term improvements.
A limitation in this respect is the increasing long-term
nonrespondent rate (i. e. proportion of patients not
returning the follow-up questionnaire: 17%, 23%, 27%,
and 39% after 12, 18, 24, and 48 months, respectively).
However, nonrespondents and respondents at 48-month
follow-up did not differ regarding baseline characteristics
Table 4 Clinical outcomes 0-48 months
Outcome (range) Age years N 0 months 48 months 0-48 month difference* SRM
Mean (95%-CI) Mean (95%-CI) Mean (95%-CI) P-value
All diagnoses
Symptom Score (0-10)
-All patients 1-75 1501 6.09 (6.00-6.18) 3.26 (3.14-3.37) 2.83 (2.71-2.96) <0.001 1.13
-Adults 17-75 1067 6.07 (5.96-6.17) 3.41 (3.27-3.54) 2.66 (2.51-2.81) <0.001 1.09
-Children 1-16 434 6.15 (5.98-6.32) 2.90 (2.68-3.11) 3.25 (3.01-3.50) <0.001 1.25
-Art therapy 1-75 273 6.19 (6.00-6.38) 3.24 (2.98-3.50) 2.95 (2.68-3.23) <0.001 1.28
-Eurythmy therapy 1-75 791 6.23 (6.10-6.36) 3.35 (3.18-3.51) 2.88 (2.70-3.06) <0.001 1.12
-Rhythmical massage Therapy 1-75 146 6.06 (5.78-6.33) 3.56 (3.16-3.96) 2.50 (2.08-2.91) <0.001 0.98
-Medical therapy 1-75 291 5.63 (5.43-5.84) 2.88 (2.62-3.14) 2.75 (2.47-3.04) <0.001 1.12
First ranked symptom (0-10) 1-75 1491 6.42 (6.32-6.52) 3.29 (3.29-3.42) 3.13 (2.99-3.28) <0.001 1.09
CES-D (0-60) 17-75 849 21.83 (21.02-22.64) 15.34 (14.55-16.13) 6.49 (5.72-7.27) <0.001 0.56
SF-36 Physical Component 17-75 1043 42.98 (42.33-43.68) 46.67 (46.01-47.33) 3.69 (3.11-4.27) <0.001 0.39
SF-36 Mental Component 17-75 1043 37.90 (37.14-38.66) 45.41 (44.69-46.13) 7.51 (6.75-8.26) <0.001 0.60
SF-36 scales (0-100)
-Physical Function 17-75 1069 74.70 (73.28-76.13) 80.30 (78.84-81.76) 5.60 (4.38-6.82) <0.001 0.28
-Role Physical 17-75 1063 44.75 (42.38-47.12) 66.35 (63.95-68.74) 21.60 (19.03-24.17) <0.001 0.51
-Role Emotional 17-75 1059 49.32 (46.79-51.86) 70.46 (68.08-72.84) 21.14 (18.44-23.84) <0.001 0.47
-Social Functioning 17-75 1072 59.17 (57.57-60.76) 74.95 (73.43-76.47) 15.79 (14.12-17.46) <0.001 0.57
-Mental Health 17-75 1070 53.62 (52.44-54.80) 65.32 (64.12-66.52) 11.70 (10.54-12.86) <0.001 0.60
-Bodily Pain 17-75 1070 54.19 (52.47-55.91) 67.70 (66.01-69.38) 13.51 (11.84-15.17) <0.001 0.49
-Vitality 17-75 1070 38.05 (36.93-39.18) 51.72 (50.48-52.97) 13.67 (12.41-14.92) <0.001 0.65
-General Health 17-75 1061 50.22 (49.04-51.39) 59.12 (57.80-60.45) 8.91 (7.76-10.06) <0.001 0.47
Diagnosis groups
ADHD: FBB-HKS Total (0-3) 3-16 60 1.74 (1.61-1.87) 1.25 (1.08-1.41) 0.49 (0.34-0.64) <0.001 0.85
Anxiety Severity (0-10) 17-75 61 7.08 (6.61-7.55) 3.72 (2.99-4.45) 3.36 (2.67-4.06) <0.001 1.24
Asthma Severity (0-10) 2-70 88 5.50 (5.04-5.96) 3.11 (2.59-3.64) 2.39 (1.86-2.91) <0.001 0.96
Migraine Severity (0-10) 17-75 44 6.77 (6.23-7.32) 4.18 (3.34-5.02) 2.59 (1.84-3.34) <0.001 1.05
Depression: CES-D (0-60) 17-70 133 34.93 (33.58-36.27) 19.75 (17.58-21.92) 15.18 (12.94-17.41) <0.001 1.16
Low back pain: HFAQ (0-100) 17-75 73 62.13 (57.54-66.72) 75.71 (71.48-79.95 13.59 (9.83-17.34) <0.001 0.84
Low back pain: LBPRS (0-100) 17-75 72 36.61 (32.75-40.46) 27.69 (23.37-32.01) 8.92 (5.11-12.73) <0.001 0.55
Patients with available baseline values, last value carried forward. CI Confidence interval. *Positive differences indicate improvement. SRM Standardised Response
Mean effect size (minimal: < 0.20, small: 0.20-0.49, medium: 0.50-0.79, large: ≥0.80). CES-D Center for Epidemiological Studies Depression Scale, German version
[34,35], ADHD Attention Deficit Hyperactivity Symptoms, FBB-HKS Total Fremdbeurteilungsbogen für Hyperkinetische Störungen (parents’ questionnaire for ADHD
core symptoms), Total score [53,54]), HFAQ Hanover Functional Ability Questionnaire [51], LBPRS Low Back Pain Rating Scale Pain Score [52].
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at baseline), and in a telephone survey of AMOS patients,
the proportion with clinical deterioration at 24-month
follow-up was comparable in nonrespondents and re-
spondents [26]. Moreover, a general explanation for late
non-responding is the tendency of study subjects to fail
to respond to repeated administration of questionnaires.
Nonetheless, we cannot exclude that nonrespondents
may have showed less improvement than respondents at
48-month follow-up. To suppress such nonrespondent
bias, clinical outcomes were analysed after replacing
missing values with the last value carried forward. Thisprocedure was based on the assumption of a maximum
plausible extent of nonrespondent bias, namely that in
nonrespondents at 48-month follow-up, Symptom Score
would show an average of zero change from the last avail-
able score value, which was documented after average
15.7 months. The assumed average zero change among
48-month nonrespondents can be compared to the ob-
served change among 48-month respondents in the same
period, which was an average of 19% improvement. Con-
sidering this finding, and with nonrespondent analyses
showing no relevant differences between respondents and
nonrespondents, it appears unlikely that non-respondents
Figure 1 Clinical outcomes on numerical rating scales (0-10). Range from 0 (“not present”) to 10 (“worst possible”). Symptom Score: all
patients (n = 1,501). Diagnosis groups Anxiety Disorders (n = 61), Asthma (n = 88), and Migraine (n = 44).
Figure 2 Clinical outcomes on other scales. FBB-HKS Total score: Range from 0 (“not present”) to 3 (“very strong intensity”) [53,54] (Attention
Deficit Hyperactivity Symptoms group, n = 60). Center for Epidemiological Studies Depression Scale, German version: Range 0-60, higher scores
indicate more depressive symptoms [34,35] (Depression group, n = 133). Hanover Functional Ability Questionnaire: Range from 0 (“minimal
function”) to 100 (“optimal function”) [51] (Low Back Pain group n = 72). Low Back Pain Rating Scale (LBPRS) Pain Score: Range from 0 (“no pain”)
to 100 (“unbearable pain”) [52] (n = 72).
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Figure 3 SF-36 Physical and Mental Component summary measures. Higher scores indicate better health [33]. Adult patents (n = 1,043).
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the replacement of missing values with the last value
carried forward, as performed in this analysis, seems an
appropriate conservative measure in regard to nonrespon-
dent bias [55].
This was an exploratory analysis and a total of 19 clin-
ical outcomes were analyzed with a total of 26 pre-post
comparisons (Table 4), therefore the issue of multiple
hypothesis-testing arises [36]. However, all 26 comparisons
showed significant improvements with p-values < 0.001 –
a constellation that would not be expected to occur by
chance (e. g. a Bonferroni adjustment for 26 tests would
have indicated p < 0.002 as the significance level).
Relevance of study findings, comparison to other studies
In this analysis, improvements following AM treatment
persisted for 48 months. This is in keeping with the aims
of AM therapy to bring about sustained improvement
[6,7,56]. Long-term clinical outcomes of AM therapy for
chronic disease has been evaluated in four studies by other
researchers [57-60], with follow-up periods of 12 months
[57,58], 14 months [60], and 36 months [59], respect-
ively. These studies investigated AM medications [60]
or comprehensive AM therapy [57-59] for anxiety in adultTable 5 Adverse reactions in months 0-24
Therapy Reported adverse reactions (this
Users* Any react
N N (%)
AM therapies 1065 21 (2.0%)
-Eurythmy 707 13 (1.8%)
-Art therapy 242 3 (1.2%)
-Rhythmical massage 116 5 (4.3%)
Non-AM non-medication No data 26
Non-AM medication 1167 173 (14.8%
AM medication 1083 48 (4.4%)
Confirmed adverse reactions [40
AM medication 662 20 (3.0%)
AM Anthroposophic medicine, N patient numbers. *Users of AM therapies: Patients refcancer patients [57] and asthma in children [58-60] and
adults [60], treated in inpatient hospitals [57], outpatient
clinics [58-60] or primary care [59]. All studies showed
long-term improvement following AM treatment. In ac-
cordance with these studies, mostly from specialized set-
tings, this 48-month follow-up analysis from the AMOS
study in a predominantly primary care setting showed
substantial improvements in symptoms and quality of life
for patients with a broader range of chronic indications.
Long-term improvements in symptoms and quality of life
have also been observed in patients receiving other comple-
mentary therapies for similar chronic indications [61-64].
In this study, adverse reactions to AM treatment were
infrequent and mostly of mild-to-moderate intensity. This
confirms findings from other prospective studies [7,65-68]
as well as retrospective surveys [69] and pharmacovigilance
databases [70]. Also, the high level of patient satisfaction
with AM treatment in this study is in keeping with other
studies [67,71-73]. Finally, the present 48-month follow-up
analysis showed a high degree of continuity of the
physician-patient-relationship in AM settings, a quality
which is important to physicians and patients [74].
To sum up: This study confirms the findings of simi-
lar research conducted elsewhere [7,57-73] and furtheranalysis)
ion Severe intensity Therapy stopped
N (%) N (%)
4 (0.4%) 3 (0.3%)
2 (0.3% 1 (0.1%)
1 (0.4%) 0 (0.0%)
1 (0.9%) 2 (1.7%)
14 10
) 57 (4.9%) 78 (6.7%)
13 (1.2%) 33 (3.0%)
]
2 (0.3%) 10 (1.5%)
erred to the respective therapy at enrolment who definitely received therapy.
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tary therapies in chronic disease and the evaluation of
complementary treatment in long-term naturalistic out-
come studies [75,76].
Conclusions
This 48-month follow-up analysis confirmed previous
analyses from the AMOS study. Outpatients receiving
comprehensive AM treatment for chronic indications
had sustained, clinically relevant improvements of symp-
toms and quality of life. Adverse reactions to AM treat-
ment were infrequent and mostly of mild-to-moderate
intensity; patient satisfaction was high.
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